Article
DUSP1 is a key driver of disease persistence and potential therapeutic target in hairy cell leukemia.
Blood advances - 11 Aug 2026
Bohn Jan-Paul, Scheiber Alexandra, Sturm Gregor, Maurer Thomas, Mair Anna, Kugler Valentina, Feichtner Andreas, Fritz Alexandra, Torres-Quesada Omar, Jaeger Ulrich, Huber Roland, Daum Sophia, Martowicz Agnieszka, Redlinger Norbert, Pircher Andreas, Sopper Sieghart, Trajanoski Zlatko, Stefan Eduard, Salcher Stefan, Wolf Dominik
Abstract excerpt
ABSTRACT: Classic hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder characterized by the driver mutation BRAF V600E. Standard treatment with purine analogs (eg, cladribine) induces long-term remissions, but up to 25% of patients relapse early. Even when targeting BRAF V600E, residual HCL cells frequently persist in the bone marrow (BM). To identify additional biological alterations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.